Meta-analysis evaluation of the treatment of neonatal hypoxic– ischemic encephalopathy with ganglioside

Abstract

The efficacy and safety of ganglioside in the treatment of neonates who suffer from hypoxic–ischemic encephalopathy (HIE) needs to be fully evaluated. We searched the following databases: PubMed, ScienceDirect, LISTA, CNKI, Chinese biomedical literature database and Wanfang digital journals of full-text database to determine the inclusion and exclusion criteria of papers and a total of 12 papers were included after quality evaluation. Then we conducted the meta-analysis with RevMan5.0 software. The results showed that compared with the control group, the abnormal rate declined in the ganglioside-treated group (relative risk (RR)=0.27, 95% confidence interval (CI)= 0.05– 1.96). NBNA records of the 7, 10–14d neonates were improved effectively: RR (95% CI) were 2.28 (0.86–3.42) and 2.53 (1.04–2.92) respectively. Neural system sequelae incidence was reduced significantly: RR (95% CI) = 0.35: (0.15–0.79). Ganglioside treatment could effectively reduce the abnormality rate of head size, improve the neurological score, reduce the incidence of neurological sequelae, and significantly prompt clinical recovery for neonates with HIE.